Study on Patients With Rasmussen Encephalitis Treated With Adalimumab: Efficacy and Tolerance in the Short and Long Term
Condition(s) studied
Investigational drug(s) / intervention(s)
Adalimumab treatment: Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.
Study summary
Since the initial study of cases reported between 2009 and 2015, adalimumab has become in France the immunomodulatory reference treatment used after failure of corticosteroids and immunoglobulins before a possible recourse to the hemispherotomy. This observational study is intended to document the long-term efficacy and safety of Adalimumab therapy in patients with Rasmussen encephalitis.
Eligibility
Primary outcome measure(s)
- Efficiency of the treatment measured by the reduction of the number of epileptic seizures — 5 years
The change of epileptic seizures (Will be considered as a responder patient any patient with a 50% decrease in the number of seizures between the time of inclusion and 6 months after the start of treatment). This response to treatment is re-evaluated at 12 months then every 6 months for 5 years. - Efficiency of the treatment measured by the stability if the cognitive assessment — 6 months
Stability of the cognitive assessment: variation of less than 10 points on each of the different composite indices (QIT, ICV, IRF, IMT, IVT) of age-appropriate Weschler scales, between two cognitive assessments of 6 months.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Service Neuropédiatrie | Marseille | France |
More Assistance Publique Hopitaux De Marseille trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04003922 on ClinicalTrials.gov ↗ ← All trials in France